TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3673526
Drug: Cefuroxime 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 0.75 grams intravenously thrice daily for 24 hours (Group B)
Study: 3673526
Drug: Cefuroxime for
Normalized name: Cefuroxime for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime for 24 hours plus 6 days of oral cephalexin (Group A)
Study: 30160030
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL (Gla-100)
Study: 19397645
Drug: 500 U
Normalized name: lipase 4500 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 U of botulinum toxin type A (BT‐A) reconstituted 15 days before injection
Study: 19397645
Drug: 500 U
Normalized name: lipase 4500 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 U of botulinum toxin type A (BT‐A) reconstituted 8 days before injection
Study: 19397645
Drug: 500 U
Normalized name: lipase 4500 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 U of botulinum toxin type A (BT‐A) reconstituted 8 hours before injection
Study: 16167153
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish treatment without tooth separation (Control group, n=26)
Study: 788910
Drug: Dihydergot (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydergot (2.5 mg, 3 times a day for 4 weeks)
Study: 31536654
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus in combination with mycophenolate mofetil (MMF)
Study: 31536654
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus in combination with sirolimus
Study: 31536654
Drug: Prolonged-release tacrolimus-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus-based therapy
Study: 24242999
Drug: Arterolane (RBx11160)
Normalized name: Arterolane
DrugBank: Arterolane (DB19027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterolane (RBx11160) maleate 25, 50, 100, 200 mg multiple oral doses
Study: 17889468
Drug: Atuna racemosa
Normalized name: Platanus racemosa pollen
DrugBank: Platanus racemosa pollen (DB10393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atuna racemosa extract (MIC=16-32 microg/mL)
Study: 1928220
Drug: EDTA infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA infusions (50 mg/kg over three hours)
Study: 31914959
Drug: Pamoja Tunaweza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamoja Tunaweza (a locally adapted version of Trauma-focused Cognitive Behavioral Therapy)
Study: 30672193
Drug: Blood-letting and
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-letting and cupping therapy combined with basic treatment for 2 weeks, 3 times a week, once every other day.
Study: 22406052
Drug: Group integrated
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group integrated cognitive‐behavioral therapy for 6 months
Study: 12434950
Drug: rhTPO and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO and G-CSF
Study: 12434950
Drug: Control (G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (G-CSF only)
Study: 7792736
Drug: diet ML
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: diet ML (C12:0 + C14:0)
Study: 31983575
Drug: VIA-2291 (Atreleuton)
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIA-2291 (Atreleuton) 100 mg
Study: 31983575
Drug: VIA-2291 (Atreleuton)
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIA-2291 (Atreleuton) (25 mg, 50 mg)
Study: 31541251
Drug: Coated implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated implant (CI; Synovex‐One Feedlot)
Study: 31541251
Drug: Implants (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants (both CI and NC)
Study: 31541251
Drug: Non-coated implant
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-coated implant (NC; Synovex‐PLUS)
Study: 31541251
Drug: No implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No implant (NI)
Study: 27680592
Drug: Inulin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (8 g/d)
Study: 27680592
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 8 g/d)
Study: 23290598
Drug: Memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20 mg orally daily for 26 weeks
Study: 21240683
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (ZOL) 4 mg every 4 weeks
Study: 19126811
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (n = 134)
Study: 16954546
Drug: Diagnostic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic doses of 2, 1, and 0.5 mCi (74, 37, and 18.5 MBq)
Study: 16954546
Drug: Therapeutic doses
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic doses of 150 and 30 mCi (5,550 and 1,110 MBq)
Study: 11562514
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose sulfited wine challenge
Study: 3630583
Drug: Ranitidine 2
Normalized name: ranitidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 2 mg kg‐1
Study: 3630583
Drug: Ranitidine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 2.5 mg kg‐1
Study: 3630583
Drug: Ranitidine 3
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 3 mg kg‐1
Study: 3630583
Drug: Ranitidine 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 3.5 mg kg‐1
Study: 16791019
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation among women with low serum retinol (< 0.7 micromol/l)
Study: 16791019
Drug: Severe anaemia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe anaemia (haemoglobin < 70 g/l)
Study: 10697447
Drug: Budesonide, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 1200 mcg daily for 6 months followed by 800 mcg daily for 30 months
Study: 30334633
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg subcutaneously at baseline, Weeks 1, 2, 3, and 4, and every 4 weeks thereafter
Study: 24366788
Drug: Ropivacaine (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (0.5% concentration, 0.5 ml/kg)
Study: 24366788
Drug: Bupivacaine (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.5% concentration, 0.5 ml/kg)
Study: 21970660
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet (T)
Study: 21970660
Drug: Branded formulations
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulations of both drugs co-administered in separate tablets (R)
Study: 26446709
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (CBT)
Study: 26312852
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (Control)
Study: 27062956
Drug: Honey consumption
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey consumption (2.5 g/kg body weight per dose, twice weekly for 12 weeks)
Study: 20517177
Drug: Evl trough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evl trough levels >= 3 ng/mL
Study: 20517177
Drug: Evl trough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evl trough levels < 3 ng/mL
Study: 20517177
Drug: Low-dose Tac
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Tac
Study: 20517177
Drug: Standard-dose Tac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose Tac
Study: 19057271
Drug: erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: erlotinib (150 mg PO per day)
Study: 14584383
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment failures (in adults)
Study: 10928213
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cognitive and action strategies
Study: 29384848
Drug: Short‐cycle therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short‐cycle therapy (SCT)
Study: 15730346
Drug: Venlafaxine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (150 mg daily)
Study: 22516666
Drug: Pregabalin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (200 mg daily)
Study: 19102944
Drug: rhIL-11 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 (3 mg/d)
Study: 15718048
Drug: 6-[18F]fluoro-L-dopa (Fdopa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-[18F]fluoro-L-dopa (Fdopa) PET scan
Study: 27150916
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of Tranexamic Acid (TXA) daily
Study: 28525614
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg lidocaine
Study: 26222347
Drug: Transversus abdominis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus abdominis plane block (TAPB) with 15 mL of 0.5% ropivacaine per side
Study: 26222347
Drug: Rectus sheath
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectus sheath block (RSB) with 15 mL of 0.5% ropivacaine per side
Study: 21150627
Drug: Ultrasound-aided ipsilateral-dominant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-aided ipsilateral-dominant block using 6 ml of lidocaine 1.5%
Study: 12616662
Drug: Oral thrombin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thrombin inhibitor LB-30057 (CI-1028)
Study: 6987113
Drug: Viloxazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine (100 to 200 mg)
Study: 22879630
Drug: Atorvastatin followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin followed by metformin 1500 mg daily
Study: 17397460
Drug: High-dose paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose paracetamol (20 mg kg(‐1))
Study: 17397460
Drug: Usual-dose paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-dose paracetamol (15 mg kg(‐1))
Study: 15721993
Drug: Estrogen-gestagen combination
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-gestagen combination drug (17beta-estradiol+norethisterone acetate) with antipsychotic drug
Study: 12010380
Drug: Mouth-dispersible aspirin
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth-dispersible aspirin 900 mg
Study: 9447289
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) 15 mg once daily (group S)
Study: 9447289
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) 10 mg 3 times daily (group C)
Study: 9133510
Drug: Lovastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 80 mg/d
Study: 26787644
Drug: Stepwise oral
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise oral misoprostol (50µg followed by two doses of 100µg)
Study: 26787644
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (three doses of 25µg inserted at intervals of 4h)
Study: 26787644
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (oral and vaginal misoprostol)
Study: 9331138
Drug: EP (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP (carboplatin AUC 6 IV over 30 to 60 minutes on day 1, etoposide 120 mg/m2 IV days 1 to 3)
Study: 3128114
Drug: Cefotetan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (1 gm single dose)
Study: 16725163
Drug: HCA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCA (3 x 500 mg/day)
Study: 14711956
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (Fraxiparine)
Study: 11346808
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg parathyroid hormone (1-34)
Study: 28252590
Drug: Antiviral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral and immunotropic drugs
Study: 25391431
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (two sessions/week)
Study: 25391431
Drug: Citicoline 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 300 mg/day (control)
Study: 21702232
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 10 mg/Kg bodyweight twice a day for five days
Study: 21702232
Drug: Metronidazole (MTZ)
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MTZ) 15 mg/Kg bodyweight divided in three daily doses for five days
Study: 12826991
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) daily
Study: 12826991
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) targeted
Study: 29280355
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily
Study: 8902432
Drug: hydroxy‐gli (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxy‐gli (1.5 mg)
Study: 1745700
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 100 mg/wk
Study: 1745700
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 300 mg/wk
Study: 1745700
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 100 mg/wk
Study: 14764787
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 300 mg/wk
Study: 1745700
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (except ND 100 mg/wk)
Study: 30465366
Drug: Other oral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral therapy or insulin therapy (used for >=2 years)
Study: 26071208
Drug: TC-5619 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC-5619 (both doses)
Study: 24182413
Drug: GnRH‐agonist triggering
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐agonist triggering and luteal support with oral estradiol (2 mg/8 hours) and vaginal progesterone (200 mg/12 hours)
Study: 24182413
Drug: GnRH‐a and
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a and a single bolus of 60 μg of recombinant hCG on oocyte pickup
Study: 24182413
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg of recombinant hCG for trigger and standard luteal support
Study: 23158484
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 µg oral selenium yeast daily for 6 months)
Study: 16169792
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment plus patient education program (group B)
Study: 16169792
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (group A)
Study: 8535036
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment with a brief cognitive‐behavioral intervention
Study: 8535036
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment without a brief cognitive‐behavioral intervention
Study: 30548935
Drug: sirolimus +
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sirolimus + low dose tacrolimus (Tac group)
Study: 14709838
Drug: 0.5 microg
Normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microg of daily oral calcitriol for 28 days
Study: 14709838
Drug: 0.5 microg
Normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microg of daily oral calcitriol for 24 weeks (after initial 28 days)
Study: 17571254
Drug: Neoral (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (200 mg cyclosporine A)
Study: 9818105
Drug: propofol i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol i.v. (6‐12 mg.kg‐1.hr‐1)
Study: 7030223
Drug: Milk supplement
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplement (1 pint of milk a day at half price)
Study: 7030223
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no milk supplement)
Study: 28626102
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/(kg·h) after a bolus infusion at 0.5 μg/kg for 10 min before anesthesia induction)
Study: 28626102
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal saline infusion)
Study: 25115871
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir (600 mg once daily)
Study: 29284320
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir
Study: 18095518
Drug: Warfarin (INR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR; range 2‐3) for the first three months, followed by ASA (100 mg/day)
Study: 11161544
Drug: Nutrison Multi
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrison Multi Fibre (NMF) administered orally
Study: 11161544
Drug: Nutrison Multi
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrison Multi Fibre (NMF) administered nasogastrically
Study: 9433337
Drug: Current medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current medication discontinuation
Study: 7736475
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus furosemide (mean dose = 248 mg)
Study: 11484961
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 on days 1, 8, and 15, and etoposide 80 mg/m2 on days 8, 9, and 10 of a 28-day cycle
Study: 7982185
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous bolus recombinant interleukin-2 (rIL-2)
Study: 1091935
Drug: Antibiotic mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic mouth rinse (CC10232) used twice a day for one week
Study: 31715434
Drug: Third‐generation drug‐eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third‐generation drug‐eluting stents for primary PCI
Study: 19893109
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (Ringer solution 1 ml/kg/h)
Study: 17028485
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Study: 17028485
Drug: Insulin-sensitizing and
Normalized name: insulin degludec and liraglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitizing and antihyperglycemic agents
Study: 9427987
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of a mixture of balanced salt solution, 2% lidocaine, 0.5% bupivacaine, and hyaluronidase
Study: 9427987
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of a mixture of balanced salt solution, 2% lidocaine, 0.5% bupivacaine, and hyaluronidase
Study: 8424029
Drug: Discontinue breast-feeding,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue breast-feeding, substitute formula and administer phototherapy
Study: 8424029
Drug: Continue breast-feeding,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue breast-feeding, administer phototherapy
Study: 3308702
Drug: Cream (saturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream (saturated fat)
Study: 27204
Drug: Promethazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (10 mg)
Study: 6398313
Drug: Thymopentin 50
Normalized name: Thymopentine
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin 50 mg via prolonged i.v. injection, 3 times weekly for 3 to 20 weeks.
Study: 6398313
Drug: Different s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different s.c. doses of thymopentin in a crossover fashion for more than two years.
Study: 6398313
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment and medication-free intervals.
Study: 29768139
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg subcutaneously every 4 weeks